Skip to main content

Research Repository

Advanced Search

Rational design, synthesis, and pharmacological evaluation of a cohort of novel beta-adrenergic receptors ligands enables an assessment of structure-activity relationships

Tricomi, Jacopo; Landini, Luca; Nieddu, Valentina; Cavallaro, Ugo; Baker, Jillian; Papakyriakou, Athanasios; Richichi, Barbara

Rational design, synthesis, and pharmacological evaluation of a cohort of novel beta-adrenergic receptors ligands enables an assessment of structure-activity relationships Thumbnail


Authors

Jacopo Tricomi

Luca Landini

Valentina Nieddu

Ugo Cavallaro

JILLIAN BAKER jillian.baker@nottingham.ac.uk
Professor of Drug Discovery and Respiratory Medicine

Athanasios Papakyriakou

Barbara Richichi



Abstract

Biomedical applications of molecules that are able to modulate β-adrenergic signaling have become increasingly attractive over the last decade, revealing that β-adrenergic receptors (β-ARs) are key targets for a plethora of therapeutic interventions, including cancer. Despite successes in β-AR drug discovery, identification of β-AR ligands that are useful as selective chemical tools in pharmacological studies of the three β-AR subtypes, or lead compounds for drug development is still a highly challenging task. This is mainly due to the intrinsic plasticity of β-ARs as G protein-coupled receptors in conjunction with the requirement for functional receptor subtype selectivity, tissue specificity and minimal off-target effects. With the aim to provide insight into structure-activity relationships for the three β-AR subtypes, we have synthesized and obtained the pharmacological profile of a series of structurally diverse compounds (named MC) that were designed based on the aryloxy-propanolamine scaffold of SR59230A. Comparative analysis of their predicted binding mode within the active and inactive states of the receptors in combination with their pharmacological profile revealed key structural elements that control their activity as agonists or antagonists, in addition to clues about substituents that mediate selectivity for one receptor subtype over the others. We anticipate that these results will facilitate selective β-AR drug development efforts.

Citation

Tricomi, J., Landini, L., Nieddu, V., Cavallaro, U., Baker, J., Papakyriakou, A., & Richichi, B. (2023). Rational design, synthesis, and pharmacological evaluation of a cohort of novel beta-adrenergic receptors ligands enables an assessment of structure-activity relationships. European Journal of Medicinal Chemistry, 246, Article 114961. https://doi.org/10.1016/j.ejmech.2022.114961

Journal Article Type Article
Acceptance Date Nov 22, 2022
Online Publication Date Nov 29, 2022
Publication Date Jan 15, 2023
Deposit Date Nov 24, 2022
Publicly Available Date Nov 30, 2023
Journal European Journal of Medicinal Chemistry
Print ISSN 0223-5234
Electronic ISSN 1768-3254
Peer Reviewed Peer Reviewed
Volume 246
Article Number 114961
DOI https://doi.org/10.1016/j.ejmech.2022.114961
Keywords G-protein-coupled receptors; β-adrenergic receptors; aryloxy propanolamine; molecular docking; β-blocker; β-agonist; β-antagonist
Public URL https://nottingham-repository.worktribe.com/output/14036453
Publisher URL https://www.sciencedirect.com/science/article/pii/S0223523422008637?via%3Dihub

Files





You might also like



Downloadable Citations